1. Home
  2. ODTX vs PRCT Comparison

ODTX vs PRCT Comparison

Compare ODTX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Odyssey Therapeutics Inc. Common Stock

ODTX

Odyssey Therapeutics Inc. Common Stock

N/A

Current Price

$18.18

Market Cap

875.1M

Sector

Health Care

ML Signal

N/A

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$18.57

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODTX
PRCT
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
875.1M
1.0B
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
ODTX
PRCT
Price
$18.18
$18.57
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$35.44
AVG Volume (30 Days)
246.6K
1.5M
Earning Date
N/A
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1.71
EPS
N/A
N/A
Revenue
N/A
$308,054,000.00
Revenue This Year
N/A
$31.34
Revenue Next Year
N/A
$24.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
37.22
52 Week Low
$15.10
$16.67
52 Week High
$20.00
$49.90

Technical Indicators

Market Signals
Indicator
ODTX
PRCT
Relative Strength Index (RSI) 53.31 39.52
Support Level $15.10 $16.67
Resistance Level $19.60 $29.27
Average True Range (ATR) 1.32 0.98
MACD 0.16 0.17
Stochastic Oscillator 72.33 45.66

Price Performance

Historical Comparison
ODTX
PRCT

About ODTX Odyssey Therapeutics Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Share on Social Networks: